Clinical trials
PTCL clinical trials
Below are recruiting ptcl clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05967949Recruiting
Chidamide maintenance after PTCL first treatment
This study looks back at people with PTCL who, after their initial first treatment, received chidamide as a continuing (maintenance) therapy. It aims to understand how effective and tolerated this approach may be in real-world care.
Nanjing, JiangsuAges 18 years+ - NCT07372352RecruitingPhase 2
Combination therapy for relapsed or refractory T-cell lymphoma
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Suzhou, JiangsuAges 18 years+ - NCT06855823RecruitingPhase 1/Phase 2
Study of golidocitinib plus pomalidomide for relapsed/refractory PTCL
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–80 - NCT07143929RecruitingPhase 1
CD7-targeted CAR-T therapy for relapsed or refractory peripheral T-cell lymphoma
This trial tests a new type of immunotherapy called CAR-T that targets a protein called CD7 on cancer cells. It is for people with peripheral T-cell lymphoma that has come back or not responded to at least one prior treatment.
BeijingAges 18–80 - NCT06137144RecruitingPhase 1/Phase 2
AZD3470 for lymphoma that has come back or not responded
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
Duarte, CaliforniaAges 12 years+ - NCT05475925RecruitingPhase 1/Phase 2
Test drug DR-01 for specific blood cancer types
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT04747236RecruitingPhase 2
Study of oral azacytidine plus romidepsin for relapsed T-cell lymphoma
This trial tests whether an oral drug (azacytidine) plus romidepsin works better than a standard “doctor’s choice” treatment for people with relapsed or refractory peripheral T-cell lymphoma. It’s for adults whose disease has come back or did not respond after prior treatment.
Long Beach, CaliforniaAges 18 years+ - NCT05931263RecruitingPhase 3
Tested Chi-BEAM vs BEAM before stem cell transplant for lymphoma
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
Nanjing, JiangsuAges 18–65 - NCT05675813RecruitingPhase 1/Phase 2
Genetic test-guided treatment for newly diagnosed peripheral T-cell lymphoma
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06739265RecruitingPhase 1/Phase 2
Golidocitinib plus CHOP for new T-cell lymphoma
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
BeijingAges 18–70 - NCT07414758RecruitingPhase 3
Golidocitinib vs placebo for PTCL maintenance after first chemo
This trial tests whether a daily pill called golidocitinib can keep your PTCL from coming back after you've had a good response to your first chemotherapy. The study compares the drug to a placebo (a pill with no active medicine) to see if it helps prevent relapse.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07162012RecruitingEarly Phase 1
Cell therapy for EBV-positive lymphoma
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
ShanghaiAges 18–70 - NCT06925464RecruitingPhase 1/Phase 2
Modified immune cells for T-cell lymphoma
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 14–70 - NCT07072221Recruiting
Matching drugs trial for relapsed T-cell lymphoma
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
Suzhou, JiangsuAges 18 years+ - NCT07074457Recruiting
Study of two drugs for CD30+ T-cell lymphoma
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
Suzhou, JiangsuAges 18–75 - NCT07018752RecruitingPhase 1/Phase 2
Testing new drug combos for relapsed T-cell lymphoma
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
CaenAges 18 years+ - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70 - NCT06909877RecruitingPhase 1/Phase 2
Study of HH2853 for relapsed or refractory peripheral T-cell lymphoma
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Chengdu, ChengduAges 18–75 - NCT06874946RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for relapsed T-cell leukemia or lymphoma
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
Beijing, Beijing MunicipalityAges 3–70 - NCT06810778RecruitingPhase 1/Phase 2
Duvelisib plus venetoclax for relapsed PTCL
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06495723RecruitingPhase 1/Phase 2
Antibody therapy for relapsed T-cell lymphoma
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
CaenAges 18 years+
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ptcl?
- Yes. Clin2 currently lists 28 recruiting ptcl studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ptcl trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ptcl trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.